Answers are grounded in this paper and cite their sources.
Background: OXYOP was a national multicenter (six participating centers) clinical study investigating the safety and performance of the oxygen carrier M101 (HEMO2life[Formula: see text] used ex vivo as an additive to the preservation solution in kidney transplantation. Methods: A total of 60 consecutive grafts treated with HEMO2life[Formula: see text] were included between March 3rd and December 8th, 2016. Grafts were preserved either in static cold storage (standard donor) or on machine perfusion (extended criteria donor). To evaluate the safety and performance of HEMO2life[Formula: see text], we compared the experimental group with a control group consisting of the contralateral kidneys (the paired kidneys that did not receive HEMO2life[Formula: see text]. Results: This study reports the follow-up results of OXYOP patients after 48 months. We found a statistical difference in terms of patient survival at 48-month post-transplantation (98.3% with HEMO2life[Formula: see text] vs 86% without HEMO2life[Formula: see text], [Formula: see text] 0.016). Importantly, more patients in the control group were converted from calcineurin inhibitors to belatacept because of poor renal function vs none in the HEMO2life[Formula: see text] group. Conclusions: These results demonstrated the major benefit of HEMO2life[Formula: see text]in renal transplant preservation. HEMO2life[Formula: see text]is the first hemoglobin-based oxygen carrier whose beneficial effect in organ preservation was established after 1 year and this is confirmed at 4-year post-transplant.
No takes yet. Share an insight, caveat, or question.
Franck Zal (2024) studied this question.